首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3759篇
  免费   176篇
  国内免费   43篇
耳鼻咽喉   96篇
儿科学   60篇
妇产科学   87篇
基础医学   377篇
口腔科学   59篇
临床医学   317篇
内科学   1153篇
皮肤病学   89篇
神经病学   250篇
特种医学   191篇
外科学   637篇
综合类   12篇
一般理论   1篇
预防医学   75篇
眼科学   57篇
药学   180篇
中国医学   3篇
肿瘤学   334篇
  2023年   25篇
  2022年   54篇
  2021年   70篇
  2020年   49篇
  2019年   67篇
  2018年   95篇
  2017年   79篇
  2016年   86篇
  2015年   92篇
  2014年   127篇
  2013年   177篇
  2012年   254篇
  2011年   255篇
  2010年   142篇
  2009年   166篇
  2008年   294篇
  2007年   301篇
  2006年   255篇
  2005年   227篇
  2004年   237篇
  2003年   155篇
  2002年   180篇
  2001年   56篇
  2000年   41篇
  1999年   47篇
  1998年   43篇
  1997年   28篇
  1996年   35篇
  1995年   24篇
  1994年   24篇
  1993年   24篇
  1992年   33篇
  1991年   28篇
  1990年   25篇
  1989年   16篇
  1988年   19篇
  1987年   11篇
  1986年   8篇
  1985年   8篇
  1984年   18篇
  1983年   7篇
  1982年   13篇
  1981年   13篇
  1980年   6篇
  1979年   6篇
  1978年   8篇
  1976年   4篇
  1974年   3篇
  1973年   5篇
  1969年   4篇
排序方式: 共有3978条查询结果,搜索用时 15 毫秒
91.
Several studies have shown a significant adenoma miss rate up to 35% during screening colonoscopy, especially in patients with diminutive adenomas. The use of artificial intelligence(AI) in colonoscopy has been gaining popularity by helping endoscopists in polyp detection, with the aim to increase their adenoma detection rate(ADR) and polyp detection rate(PDR) in order to reduce the incidence of interval cancers. The efficacy of deep convolutional neural network(DCNN)-based AI system for polyp detection has been trained and tested in ex vivo settings such as colonoscopy still images or videos. Recent trials have evaluated the real-time efficacy of DCNN-based systems showing promising results in term of improved ADR and PDR. In this review we reported data from the preliminary ex vivo experiences and summarized the results of the initial randomized controlled trials.  相似文献   
92.

Background After the expiry of the patent of reference etanercept, several biosimilars have been developed, including SB4. Objective To study safety and efficacy of SB4 in psoriatic patients previously treated with etanercept and in the etanercept naive ones. Method Patients affected by moderate to severe psoriasis and/or psoriatic arthritis attending the Psoriasis Center of Florence University, treated with SB4 were enrolled in the study. Patients were divided in two cohorts. Cohort 1 included 32 patients who were switched from previous etanercept, cohort 2 included 12 patients who were naive to etanercept. Results Evaluation of the efficacy of SB4 in cohort 1 patients revealed rates of clinical remission (defined as both PASI and/or DAS28 increase <?10%) of 92% and 64% for psoriasis and psoriatic arthritis respectively. In cohort 2 at week 24 PASI 75 was observed in 75% of patients. Conclusion In our experience switching from originator to SB4 in psoriatic patients seems not to influence efficacy, especially cutaneous manifestations, over a median observational period of 24 weeks.

  相似文献   
93.
94.
95.
96.
97.
98.
99.
Type 1 diabetes triggers protein kinase C (PKC)-dependent NADPH oxidase activation in the renal medullary thick ascending limb (mTAL), resulting in accelerated superoxide production. As acute exposure to superoxide stimulates NaCl transport by the mTAL, we hypothesized that diabetes increases mTAL Na(+) transport through PKC-dependent and NADPH oxidase-dependent mechanisms. An O(2)-sensitive fluoroprobe was used to measure O(2) consumption by mTALs from rats with streptozotocin-induced diabetes and sham rats. In sham mTALs, total O(2) consumption was evident as a 0.34±0.03 U change in normalized relative fluorescence (ΔNRF)/min per mg protein. Ouabain (2 mmol/L) reduced O(2) consumption by 69±4% and 500 μmol/L furosemide reduced O(2) consumption by 58±8%. Total O(2) consumption was accelerated in mTAL from diabetic rats (0.74±0.07 ΔNRF/min/mg protein; P<0.05 versus sham), reflecting increases in ouabain- and furosemide-sensitive O(2) consumption. NADPH oxidase inhibition (100 μmol/L apocynin) reduced furosemide-sensitive O(2) consumption by mTAL from diabetic rats to values not different from sham. The PKC inhibitor calphostin C (1 μmol/L) or the PKCα/β inhibitor G?6976 (1 μmol/L) decreased furosemide-sensitive O(2) consumption in both groups, achieving values that did not differ between sham and diabetic. PKCβ inhibition had no effect in either group. Similar inhibitory patterns were evident with regard to ouabain-sensitive O(2) consumption. We conclude that NADPH oxidase and PKC (primarily PKCα) contribute to an increase in O(2) consumption by the mTAL during type 1 diabetes through effects on the ouabain-sensitive Na(+)-K(+)-ATPase and furosemide-sensitive Na(+)-K(+)-2Cl(-) cotransporter that are primarily responsible for active transport Na(+) reabsorption by this nephron segment.  相似文献   
100.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号